Role of intratympanic glucocorticoid treatment in sudden hearing loss
© 2024. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature..
Idiopathic sudden sensorineural hearing loss (ISSNHL) is one of the most common diseases in otolaryngology. Its etiology remains unknown. Furthermore, there is only a low level of evidence for the efficacy of established treatment modalities. In addition to systemic glucocorticoids, intratympanic corticosteroid treatment (ICT) has become increasingly important for treatment of ISSNHL. Different application strategies and treatment regimens have been described; however, uniform standards do not yet exist. ICT may be used for primary treatment as well as salvage therapy. Current data from meta-analyses show no benefit of intratympanic versus systemic primary therapy for sudden hearing loss (moderate evidence) but suggest a benefit of intratympanic secondary treatment over no treatment or placebo (high effect size, low evidence). Regarding combination of systemic and local glucocorticoid therapy in primary treatment of hearing loss, there may be a small benefit over systemic treatment alone (low effect size, low evidence).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:72 |
|---|---|
| Enthalten in: |
HNO - 72(2024), 4 vom: 13. März, Seite 291-302 |
| Sprache: |
Deutsch |
|---|
| Weiterer Titel: |
Stellenwert der intratympanalen Glukokortikoidtherapie in der Behandlung des Hörsturzes |
|---|
| Beteiligte Personen: |
Hoch, Stephan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
7S5I7G3JQL |
|---|
| Anmerkungen: |
Date Completed 25.03.2024 Date Revised 25.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00106-024-01424-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368414485 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368414485 | ||
| 003 | DE-627 | ||
| 005 | 20240325234836.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240214s2024 xx |||||o 00| ||ger c | ||
| 024 | 7 | |a 10.1007/s00106-024-01424-z |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1346.xml |
| 035 | |a (DE-627)NLM368414485 | ||
| 035 | |a (NLM)38351342 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a ger | ||
| 100 | 1 | |a Hoch, Stephan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Role of intratympanic glucocorticoid treatment in sudden hearing loss |
| 246 | 3 | 3 | |a Stellenwert der intratympanalen Glukokortikoidtherapie in der Behandlung des Hörsturzes |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.03.2024 | ||
| 500 | |a Date Revised 25.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature. | ||
| 520 | |a Idiopathic sudden sensorineural hearing loss (ISSNHL) is one of the most common diseases in otolaryngology. Its etiology remains unknown. Furthermore, there is only a low level of evidence for the efficacy of established treatment modalities. In addition to systemic glucocorticoids, intratympanic corticosteroid treatment (ICT) has become increasingly important for treatment of ISSNHL. Different application strategies and treatment regimens have been described; however, uniform standards do not yet exist. ICT may be used for primary treatment as well as salvage therapy. Current data from meta-analyses show no benefit of intratympanic versus systemic primary therapy for sudden hearing loss (moderate evidence) but suggest a benefit of intratympanic secondary treatment over no treatment or placebo (high effect size, low evidence). Regarding combination of systemic and local glucocorticoid therapy in primary treatment of hearing loss, there may be a small benefit over systemic treatment alone (low effect size, low evidence) | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Corticosteroids | |
| 650 | 4 | |a Hearing loss | |
| 650 | 4 | |a Inner ear | |
| 650 | 4 | |a Intratympanic injection | |
| 650 | 4 | |a Tympanic cavity | |
| 650 | 7 | |a Glucocorticoids |2 NLM | |
| 650 | 7 | |a Dexamethasone |2 NLM | |
| 650 | 7 | |a 7S5I7G3JQL |2 NLM | |
| 650 | 7 | |a Adrenal Cortex Hormones |2 NLM | |
| 700 | 1 | |a Kremper, Luisa |e verfasserin |4 aut | |
| 700 | 1 | |a Rudhart, Stefan Alexander |e verfasserin |4 aut | |
| 700 | 1 | |a Stuck, Boris Alexander |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t HNO |d 1948 |g 72(2024), 4 vom: 13. März, Seite 291-302 |w (DE-627)NLM000004588 |x 1433-0458 |7 nnns |
| 773 | 1 | 8 | |g volume:72 |g year:2024 |g number:4 |g day:13 |g month:03 |g pages:291-302 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00106-024-01424-z |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 72 |j 2024 |e 4 |b 13 |c 03 |h 291-302 | ||